Search Page

1

Cite

Share

Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide.

Bingham SJ, Buch MH, Kerr MA, Emery P, Valadäo Barcelos AT. Bingham SJ, et al. Among authors: buch mh. Arthritis Rheum. 2004 Dec;50(12):4072-3. doi: 10.1002/art.20617. Arthritis Rheum. 2004. PMID: 15593202 No abstract available.

Cite

Share

2

Cite

Share

Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis.

Ponchel F, Morgan AW, Bingham SJ, Quinn M, Buch M, Verburg RJ, Henwood J, Douglas SH, Masurel A, Conaghan P, Gesinde M, Taylor J, Markham AF, Emery P, van Laar JM, Isaacs JD. Ponchel F, et al. Blood. 2002 Dec 15;100(13):4550-6. doi: 10.1182/blood-2002-03-0671. Epub 2002 Aug 8. Blood. 2002. PMID: 12393721

Cite

Share

3

Cite

Share

FcgammaRIIIA-158V and rheumatoid arthritis: a confirmation study.

Morgan AW, Keyte VH, Babbage SJ, Robinson JI, Ponchel F, Barrett JH, Bhakta BB, Bingham SJ, Buch MH, Conaghan PG, Gough A, Green M, Lawson CA, Pease CT, Markham AF, Ollier WE, Emery P, Worthington J, Isaacs JD. Morgan AW, et al. Among authors: buch mh. Rheumatology (Oxford). 2003 Apr;42(4):528-33. doi: 10.1093/rheumatology/keg169. Rheumatology (Oxford). 2003. PMID: 12649399

Cite

Share

4

Cite

Share

Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P. Jarrett SJ, et al. Among authors: buch mh. J Rheumatol. 2003 Oct;30(10):2287-91. J Rheumatol. 2003. PMID: 14528531

Cite

Share

5

Cite

Share

The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.

Bingham SJ, Buch MH, Tennant A, Emery P. Bingham SJ, et al. Among authors: buch mh. Rheumatology (Oxford). 2004 Mar;43(3):364-8. doi: 10.1093/rheumatology/keh057. Epub 2003 Dec 1. Rheumatology (Oxford). 2004. PMID: 14657509

Cite

Share

6

Cite

Share

Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.

Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, White J, Emery P. Buch MH, et al. Arthritis Rheum. 2004 Mar;50(3):725-8. doi: 10.1002/art.20115. Arthritis Rheum. 2004. PMID: 15022311

Cite

Share

7

Cite

Share

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?

Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. Buch MH, et al. Ann Rheum Dis. 2004 Oct;63(10):1344-6. doi: 10.1136/ard.2003.014878. Epub 2004 Mar 19. Ann Rheum Dis. 2004. PMID: 15033655 Free PMC article.

Cite

Share

8

Cite

Share

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.

Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P. Buch MH, et al. Arthritis Rheum. 2005 Jan;52(1):42-8. doi: 10.1002/art.20711. Arthritis Rheum. 2005. PMID: 15641046

Cite

Share

9

Cite

Share

Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.

Ponchel F, Verburg RJ, Bingham SJ, Brown AK, Moore J, Protheroe A, Short K, Lawson CA, Morgan AW, Quinn M, Buch M, Field SL, Maltby SL, Masurel A, Douglas SH, Straszynski L, Fearon U, Veale DJ, Patel P, McGonagle D, Snowden J, Markham AF, Ma D, van Laar JM, Papadaki HA, Emery P, Isaacs JD. Ponchel F, et al. Arthritis Res Ther. 2005;7(1):R80-92. doi: 10.1186/ar1452. Epub 2004 Nov 16. Arthritis Res Ther. 2005. PMID: 15642146 Free PMC article.

Cite

Share

10

Cite

Share

Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?

Buch MH, Emery P. Buch MH, et al. Nat Clin Pract Rheumatol. 2006 Jun;2(6):288-9. doi: 10.1038/ncprheum0210. Nat Clin Pract Rheumatol. 2006. PMID: 16932704 No abstract available.

Cite

Share